TGTX
TG Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website gtherapeutics.com
- Employees(FY) 245
- ISIN US88322Q1085
Performance
+28.98%
1W
+18.32%
1M
+11.92%
3M
+67.61%
6M
+0.59%
YTD
-48.1%
1Y
Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Investment Analysis Report: TGTX
Overview
TG Therapeutics Inc. (TGTX) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $2.09 billion. In this report, we will conduct a comprehensive analysis of TGTX's financial statements to evaluate its valuation, financial...
Technical Analysis of TGTX 2024-05-03
Overview:
In analyzing the technical indicators for TGTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key indicators, we aim to offer valuable insights and recommendations for potential future price actio...
Recent News & Updates
- 2024-05-03 09:33
- 2024-05-03 07:29
- 2024-05-03 05:56
- 2024-05-02 21:33
- 2024-05-02 07:27
- 2024-05-02 03:05
- 2024-05-02 00:27
Q1 2024 TG Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-01 08:34
- 2024-05-01 08:30
- 2024-05-01 07:32
TG Therapeutics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-01 07:00
- 2024-04-30 23:53
- 2024-04-30 20:30
- 2024-04-30 19:00
- 2024-04-30 16:55
- 2024-04-30 09:35
- 2024-04-30 04:55
- 2024-04-29 21:35
- 2024-04-26 21:37
10 Best Languages to Learn for the Future(Insidermonkey)
- 2024-04-18 07:30
- 2024-04-18 07:00
- 2024-04-17 19:30
- 2024-04-17 19:00
- 2024-04-15 07:30
- 2024-04-14 19:30
- 2024-03-19 07:10
- 2024-03-13 07:07
13 Best Biotech Stocks To Buy Under $20(Insider Monkey)
- 2024-03-12 19:07
13 Best Biotech Stocks To Buy Under $20(Insidermonkey)
- 2024-03-08 07:30
- 2024-03-07 18:30
Page 1 of 6
previousnext